SCHEMBL3133737

SCHEMBL3133737

Cc1ccc(S(=O)(=O)Oc2nc(N)nc3c2CCCc2c-3cnn2C(C)(C)C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.42
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
ALDH1A1 P00352 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA4 P22748 2/20 0.33
CA9 Q16790 2/20 0.33
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
HRH2 P25021 1/20 0.30
HRH3 Q9Y5N1 1/20 0.30
DRD2 P14416 1/20 0.30
DRD1 P21728 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3137466 0.88 CYP2C19 (0.44) CYP2C19KEAP1NFE2L2ALDH1A1CYP3A4
SCHEMBL3131985 0.79 CYP2C19 (0.47) CYP2C19KEAP1NFE2L2ALDH1A1CYP3A4
SCHEMBL4877590 0.78 CYP2C19 (0.51) CYP2C19KEAP1NFE2L2ALDH1A1CYP3A4
SCHEMBL2166315 0.77 ALDH1A1 (0.49) CYP2C19KEAP1NFE2L2ALDH1A1MEN1
SCHEMBL4878194 0.75 ALDH1A1 (0.47) CYP2C19KEAP1NFE2L2ALDH1A1CYP2D6
SCHEMBL3135449 0.75 CYP2C19 (0.47) CYP2C19KEAP1NFE2L2ALDH1A1CYP3A4
SCHEMBL4876866 0.75 ALDH1A1 (0.46) CYP2C19KEAP1NFE2L2ALDH1A1CYP2D6
SCHEMBL4875369 0.74 HRH4 (0.48) CYP2C19KEAP1NFE2L2ALDH1A1CYP3A4
SCHEMBL3128908 0.73 CYP2C19 (0.47) CYP2C19KEAP1NFE2L2ALDH1A1CYP3A4
SCHEMBL4129860 0.72 CYP2C19 (0.61) CYP2C19KEAP1NFE2L2ALDH1A1HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546410-B2 Heteroaryl-fused macrocyclic pyrimidine derivatives ABBVIE INC. (US) 2013-10-01 US disclosed
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES CDK2, DPYD, CCNB1 CYP2C19 318/4885KEAP1 1172/4885NFE2L2 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.